5-MeO-DMT: An atypical psychedelic with unique pharmacology, phenomenology & risk?
Psychopharmacology – December 11, 2023
Source: PubMed
Summary
Unlike typical psychedelics, 5-MeO-DMT shows unique effects that may mirror temporal lobe seizure activity, offering clues to its therapeutic potential. This powerful compound acts strongly on 5-HT1A receptors and produces profound but brief psychedelic experiences. Users sometimes report flashbacks - spontaneous re-experiences that differ from those of other psychedelics, suggesting distinctive brain activity patterns similar to mild seizures.
Abstract
5-MeO-DMT is a tryptamine being developed as a potential antidepressant that may display a distinct therapeutic mechanism due to its unique pharmacology and subjective effects compared to typical psychedelics. In this article, we parallel the relatively distinct phenomenology and behavioral effects of the acute and post-acute effects of 5-MeO-DMT to those induced by epileptiform activity, particularly in instances within epileptogenic zones of the temporal lobes. This is done by reviewing aberrant 5-HT1A receptor functioning in epilepsy, noting that 5-MeO-DMT has notable 5-HT1A receptor agonist properties-and then comparing the acute behavioral and subjective effects induced by 5-MeO-DMT to those that occur in seizures. It might be that 5-MeO-DMT's therapeutic mechanism is partly mediated by evoking temporary epileptiform activity, suggesting a similarity to electroconvulsive therapy. It is also noted that "reactivations," the sudden re-experiencing of drug effects common after 5-MeO-DMT but not after typical psychedelics, may suggest that 5-MeO-DMT produces recurrent epileptiform activity. Overall, this review indicates that further evaluation of 5-MeO-DMT's unique mechanisms in research settings and among naturalistic users are warranted.